Usefulness of an Initial Single Intravenous Immunoglobulin Therapy for Kawasaki Disease

α
Toshimasa Nakada
Toshimasa Nakada
α Aomori Prefectural Central Hospital

Send Message

To: Author

Usefulness of an Initial Single Intravenous Immunoglobulin Therapy for Kawasaki Disease

Article Fingerprint

ReserarchID

H9OO2

Usefulness of an Initial Single Intravenous Immunoglobulin Therapy for Kawasaki Disease Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

Kawasaki disease is an acute systemic vasculitis of unknown cause that affects mainly infants and children. Coronary artery lesions (CAL) are one of the most important complications of this disease. An appropriate therapy during acute phase of Kawasaki disease to prevent large CAL has not been established. Recent studies disclosed that aspirin and flurbiprofen appeared to have a negative impact on the suppressive effects of initial intravenous immunoglobulin (IVIG) therapy on CAL development in the acute phase of Kawasaki disease and that an initial single IVIG therapy with delayed administration of anti-inflammatory drugs might be useful for prevention of large CAL. Furthermore, recent study disclosed that variable factors including IVIG resistance, responsiveness, and relapse of disease were associated with CAL complications and that an initial single IVIG therapy may be useful for the prevention of large CAL caused by different factors of Kawasaki disease.

References

24 Cites in Article
  1. Jane Burns,Mary Glodé (2004). Kawasaki syndrome.
  2. F Muller,W Knirsch,P Harpes,R Pretre,B Valsangiacomo,O Kretschmar (2009). Long-term follow-up of acute changes in coronary artery diameter caused by Kawasaki disease: risk factors for development of stenotic lesions.
  3. E Tsuda,T Kamiya,Y Ono,K Kimura,K Kurosaki,S Echigo (2005). Incidence of Stenotic Lesions Predicted by Acute Phase Changes in Coronary Arterial Diameter During Kawasaki Disease.
  4. T Nakada (2015). Prevention of large coronary artery lesions caused by Kawasaki disease.
  5. Kenshi Furusho,Hiroyuki Nakano,Keisuke Shinomiya,Tokio Tamura,Yutaka Manabe,Masaharu Kawarano,Kiyoshi Baba,Tetsuro Kamiya,Nobuyuki Kiyosawa,Tadashi Hayashidera,Osamu Hirose,Tatsuo Yokoyama,Kunizo Baba,Chuzo Mori (1984). HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE.
  6. J Newburger,M Takahashi,A Beiser (1991). Single intravenous infusion of gamma globulin as compared with four infusion in the treatment of acute Kawasaki syndrome.
  7. Pediatric Cardiology (2014). Cardiac Surgery committee for development of guidelines for medical treatment of acute Kawasaki disease. Guidelines for medical treatment of acute Kawasaki disease: report of the Research committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).
  8. T Kobayashi,T Saji,T Otani (2012). Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial.
  9. Adriana Tremoulet,Sonia Jain,Preeti Jaggi,Susan Jimenez-Fernandez,Joan Pancheri,Xiaoying Sun,John Kanegaye,John Kovalchin,Beth Printz,Octavio Ramilo,Jane Burns (2014). Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
  10. Toshimasa Nakada (2015). Background Factors Associated with the Complications of Coronary Artery Lesions Caused by Kawasaki Disease.
  11. T Yahata,C Suzuki,A Yoshikawa (2014). Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease.
  12. J Baumer,Samantha Love,Amit Gupta,Linda Haines,Ian Maconochie,Jaspal Dua (2006). Salicylate for the treatment of Kawasaki disease in children.
  13. K Hsieh,K Weng,C Lin (2004). Treatment of acute Kawasaki disease: aspirin's role in the febril stage revisited.
  14. Goni Lee,Seung Lee,Young Hong,Sejung Sohn (2013). Is High-Dose Aspirin Necessary in the Acute Phase of Kawasaki Disease?.
  15. H Ito,N Kiyosawa (2002). Effectiveness of aspirin therapy in acute phase of Kawasaki disease.
  16. T Nakada (2012). Difference in the prevalence of coronary arterial lesions in Kawasaki disease according to the time of initiation of additional aspirin or flurbiprofen therapy.
  17. T Nakada (2015). Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease.
  18. Chahid Benammar,Aziz Hichami,Akadiri Yessoufou,Anne-Marie Simonin,Meriem Belarbi,Hocine Allali,Naim Khan (2010). Zizyphus lotus L. (Desf.) modulates antioxidant activity and human T-cell proliferation.
  19. Matthew Buckland,Giovanna Lombardi (2009). Aspirin and the Induction of Tolerance by Dendritic Cells.
  20. L Huang,G Mackenzie,N Ouyang (2011). The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvantinduced arthritis in rats.
  21. Y Inoue,T Kaifu,A Sugahata-Tobinai (2007). Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice.
  22. M Yamamoto,K Kobayashi,Y Ishikawa (2010). The inhibitory effects of intravenous administration of rabbit immunoglobulin G on airway inflammation are dependent upon Fcc receptor II b on CD11c(?) dendritic cells in a murine model.
  23. Y Zhang,X Huang,M Kang (2006). Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease.
  24. A Ashida,N Ozaki,K Kishi,H Katayama,K Okasora,H Tamai (2013). A case report of refractory Kawasaki disease with bilateral giant coronary aneurysms treated with intravenous immunoglobulin and prednisolone combination therapy.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Toshimasa Nakada. 2015. \u201cUsefulness of an Initial Single Intravenous Immunoglobulin Therapy for Kawasaki Disease\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 15 (GJMR Volume 15 Issue F4): .

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-F Classification: NLMC Code: WO 285
Version of record

v1.2

Issue date

November 2, 2015

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 4138
Total Downloads: 2140
2026 Trends
Related Research

Published Article

Kawasaki disease is an acute systemic vasculitis of unknown cause that affects mainly infants and children. Coronary artery lesions (CAL) are one of the most important complications of this disease. An appropriate therapy during acute phase of Kawasaki disease to prevent large CAL has not been established. Recent studies disclosed that aspirin and flurbiprofen appeared to have a negative impact on the suppressive effects of initial intravenous immunoglobulin (IVIG) therapy on CAL development in the acute phase of Kawasaki disease and that an initial single IVIG therapy with delayed administration of anti-inflammatory drugs might be useful for prevention of large CAL. Furthermore, recent study disclosed that variable factors including IVIG resistance, responsiveness, and relapse of disease were associated with CAL complications and that an initial single IVIG therapy may be useful for the prevention of large CAL caused by different factors of Kawasaki disease.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Usefulness of an Initial Single Intravenous Immunoglobulin Therapy for Kawasaki Disease

Toshimasa Nakada
Toshimasa Nakada Aomori Prefectural Central Hospital

Research Journals